GLP-1 and muscle loss: how to keep lean mass while losing weight

Losing some muscle along with fat is a normal part of losing a lot of weight, and GLP-1 medications are no exception. The reassuring part is that most of the weight people lose on these medications is fat, not muscle, and the muscle share looks similar to what happens with dieting or weight-loss surgery. The part worth acting on is that you can protect your lean mass with two well-studied habits: eating enough protein and doing resistance training. This page walks through what the body-composition research actually shows and what to do about it. For the fuller picture, see our guide to preserving muscle on a GLP-1 and our overview of starting a GLP-1 with a licensed provider.

Do you lose muscle when you lose weight on a GLP-1?

Yes, some of the weight you lose on a GLP-1 medication is lean tissue, but most of it is fat. In the STEP 1 trial of semaglutide, body weight fell by roughly 15%, and the drop in fat mass was much larger than the drop in lean body mass: total fat mass fell about 19% and visceral fat about 27%, while lean body mass fell only about 10%, a much larger relative reduction in fat than in lean tissue (review of muscle health with incretin-based therapies, 2026). Across GLP-1 trials, lean mass accounts for roughly 20% to 40% of the total weight lost, not the majority (same review). Tirzepatide showed the same pattern in its SURMOUNT-1 trial, where about 75% of the weight lost was fat mass and lean body mass fell by about 11% (same review). The plain reading is that these medications drive predominantly fat loss with a smaller, expected reduction in lean mass, rather than “melting muscle.” The branded medications behind this era are semaglutide (sold as Wegovy for weight management (Wegovy label, DailyMed) and Ozempic for type 2 diabetes (Ozempic label, DailyMed)) and tirzepatide (sold as Zepbound for weight management (Zepbound label, DailyMed) and Mounjaro for type 2 diabetes (Mounjaro label, DailyMed)). All four are FDA-approved, and Wegovy and Zepbound are indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (Wegovy label, DailyMed; FDA approval of Zepbound).

Is muscle loss on a GLP-1 worse than with other weight loss?

No, the share of weight loss that comes from lean mass on GLP-1 medications looks broadly comparable to what happens with dieting or bariatric surgery. Any substantial weight loss carries some loss of lean tissue, because the body sheds a mix of fat and fat-free mass whenever it runs an energy deficit. When researchers line up diet-based weight loss, GLP-1 medications, and surgery side by side, the absolute lean-mass losses are variable but broadly similar across all three approaches, and the loss on GLP-1 medications is not disproportionate (review of muscle health with incretin-based therapies, 2026). This matters because a lot of online commentary treats GLP-1 muscle loss as a uniquely alarming side effect. It is better understood as the ordinary cost of losing weight, which means the same countermeasures that protect muscle during any diet apply here. That said, lean mass is still worth defending, because it supports strength, day-to-day function, and the ability to keep weight off, and some clinicians consider protecting it especially important in older patients and anyone with a large amount of weight to lose.

Does losing lean mass on a GLP-1 make you weaker?

Not necessarily, because strength and physical function do not track the number on a body-composition scan one-for-one. In the SEMALEAN study of semaglutide 2.4 mg, participants lost fat steadily (total fat mass fell about 14% at seven months and about 19% by twelve months) and lean mass dropped by about 3 kg early and then stabilized, yet handgrip strength actually increased, by about 3.7 kg at seven months and 4.1 kg at twelve months (SEMALEAN study, 2026). Over the same period, the share of participants meeting criteria for sarcopenic obesity, a combination of excess fat and low muscle function, fell from 49% to 33% (SEMALEAN study, 2026). In other words, a smaller body can be a stronger and more functional body, even when a DXA scan records a modest drop in lean mass. The goal is not to keep every gram of lean tissue on the scan. It is to preserve strength, mobility, and metabolic health while the fat comes off, and that is something you can influence directly.

How much protein do you need on a GLP-1?

Aim for roughly 1 to 1.5 grams of protein per kilogram of body weight per day, and toward the higher end if you are older or managing other health conditions (review of muscle health with incretin-based therapies, 2026). For someone weighing 80 kg (about 176 lb), that works out to roughly 80 to 120 grams of protein a day. Hitting that target takes deliberate effort on a GLP-1, because these medications work partly by lowering appetite and calorie intake, so total food intake falls and it becomes easy to under-eat protein specifically (Wegovy label, DailyMed). The practical move is to treat protein as the priority at every meal, building plates around foods like eggs, dairy, fish, poultry, lean meat, tofu, legumes, and protein supplements, and eating it first when your appetite is small. Spreading protein across the day rather than loading it into one meal also helps, since evenly distributed protein stimulates more 24-hour muscle protein synthesis than a skewed intake (protein-distribution crossover trial, 2014). This is also a reason to raise the dose gradually under a provider rather than rushing to the top of the range. Semaglutide for weight management is escalated in steps over several months to reduce gastrointestinal side effects (Wegovy label, DailyMed), and the ceiling has moved: in March 2026 the FDA approved a higher-dose semaglutide, Wegovy HD (7.2 mg), now the highest approved weight-management dose, above the 2.4 mg dose used in the trials described above (FDA approval of higher-dose semaglutide, 2026). Whatever the target, slower titration keeps nausea and appetite loss manageable, which makes it easier to keep eating enough. For more on the appetite side, see how to manage GLP-1 nausea.

Does resistance training protect muscle on a GLP-1?

Yes, resistance training is the most reliable tool for holding onto muscle while you lose weight, and it works best when it is paired with enough protein. In a randomized controlled trial of adults aged 55 to 80 who were losing weight, the researchers tested a higher-protein diet (a 1.3 g/kg target versus 0.8 g/kg) and resistance training in a two-by-two design. Only the group that combined higher protein with resistance exercise significantly increased fat-free mass, by about 0.6 kg over ten weeks, while protein alone or exercise alone did not produce that gain (randomized trial in older adults, 2017). The training in that trial was straightforward and repeatable: resistance sessions three days a week, about an hour each, working the major muscle groups through movements like squats, lunges, chest press, shoulder press, rows, and step-ups, with the load increased over time (randomized trial in older adults, 2017). Reviews of GLP-1 therapy reach the same conclusion, recommending that progressive resistance training accompany treatment, especially for higher-risk patients (review of muscle health with incretin-based therapies, 2026). It is worth remembering that the weight-management approvals for these medications are for use alongside increased physical activity in the first place (FDA approval of Zepbound), so training is part of how the drugs are meant to be used, not an optional extra. Our sister site Recomp Lab covers keeping muscle through a fat-loss phase in more programming detail.

What does a muscle-smart GLP-1 plan look like?

A muscle-smart plan rests on three habits working together: enough protein, regular resistance training, and a gradual dose increase supervised by a licensed provider. The evidence is consistent that protein and resistance training are strongest as a pair rather than in isolation (randomized trial in older adults, 2017), so a reasonable starting framework is to aim for about 1 to 1.5 g/kg of protein per day, lift two to three times a week with progressive loads, and let the dose climb slowly enough that appetite loss does not sabotage your eating (review of muscle health with incretin-based therapies, 2026). None of this is a guarantee, and the right targets depend on your age, starting point, and health history, which is exactly the kind of individualization a clinical visit is for. A provider can also track function over time, since grip strength and how you feel day to day are better markers of whether a plan is working than the lean-mass line on a scan alone (SEMALEAN study, 2026). If you are weighing next steps, related reading includes what happens when you stop a GLP-1 and whether you need labs before starting a GLP-1. Some people also add MOTS-c in the hope of protecting muscle; that idea rests on mouse studies, set out in MOTS-c for weight loss.

Sources and further reading

Every clinical figure on this page traces to a peer-reviewed study or an FDA document, listed here so you can verify it directly.

• Muscle health in the modern era of incretin-based therapies (review, PMC, 2026), STEP 1 and SURMOUNT-1 body-composition figures, the “not disproportionate” comparison across weight-loss methods, and the protein and resistance-training recommendations.
• Impact of semaglutide on fat mass, lean mass and muscle function in obesity: the SEMALEAN study (PMC, 2026), fat and lean mass changes, handgrip-strength gains, and the fall in sarcopenic obesity.
• Effect of a high-protein diet and/or resistance exercise on preservation of fat-free mass during weight loss in older adults (randomized controlled trial, PMC, 2017), the trial showing protein plus resistance training together preserved fat-free mass.
• Dietary protein distribution positively influences 24-h muscle protein synthesis in healthy adults (crossover trial, J Nutr, 2014), the basis for spreading protein evenly across meals rather than loading one meal.
• FDA approves a new medication for chronic weight management (Zepbound/tirzepatide, FDA), the chronic-weight-management indication and its use alongside diet and increased physical activity.
• FDA approves higher-dose semaglutide, Wegovy HD 7.2 mg (FDA, March 2026), the current highest FDA-approved semaglutide dose for weight management, above the 2.4 mg used in the trials cited here.
• Wegovy (semaglutide) label, DailyMed, the weight-management indication (adjunct to reduced-calorie diet and increased physical activity), the appetite/calorie-intake mechanism, and the stepwise dose escalation.
• Ozempic (semaglutide) label, DailyMed and Mounjaro (tirzepatide) label, DailyMed, the type 2 diabetes indications.
• Zepbound (tirzepatide) label, DailyMed, the chronic-weight-management indication.